While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Novartis stock fell early Thursday after the drugmaker reported light sales of Cosentyx, one of its biggest moneymakers.

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

Novartis AG announced disappointing sales for a key psoriasis drug and the looming retirement of its respected finance chief, ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

Novartis ( NYSE: NVS) CEO Vas Narasimhan said the company has built up its U.S. inventories to help mitigate the impact of ...

In a final draft guidance, the committee recommended the treatment for HR-positive HER2-negative early breast cancer patients, regardless of lymph node involvement.

BERLIN ― Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong revenue growth from products such as breast cancer drug Kisqali during the second quarter.

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...